CTI BioPharma Corp.
CTI BioPharma Corp. (CTIC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctic · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CTI BioPharma Corp. (CTIC) measures how much investors pay for each dollar of the company's trailing earnings. CTIC's current PE ratio of N/A is calculated by dividing its stock price of $9.10 by its TTM earnings per share of -$0.79.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CTI BioPharma Corp.You CTIC | $1.2B | N/A | — | -$0.79 |
 Crescent Biopharma, Inc. CBIO | $476M | N/A | — | -$14.78 |
 CinCor Pharma, Inc. CINC | $1.3B | N/A | — | -$1.42 |
 EQRx, Inc. EQRX | $1.1B | 5.68x | -10.5% | $0.43 |
 Ethzilla Corp. ETHZ | $56M | N/A | — | -$5517.71 |
 Gracell Biotechnologies Inc. GRCL | $198M | N/A | — | -$44.87 |
 POINT Biopharma Global Inc. PNT | $1.3B | 7.02x | +10.5% | $1.04 |
Industry Average 2 peers with valid PE | — | 6.35x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.79 | — | |
2021-12-31 FY2021 | — | $-1.11 | — | |
2020-12-31 FY2020 | — | $-0.74 | — | |
2019-12-31 FY2019 | — | $-0.73 | — | |
2018-12-31 FY2018 | — | $-0.52 | — | |
2017-12-31 FY2017 | — | $-1.12 | — | |
2016-12-31 FY2016 | — | $-1.86 | — | |
2015-12-31 FY2015 | — | $-4.26 | — | |
2014-12-31 FY2014 | — | $-6.29 | — | |
2013-12-31 FY2013 | — | $-3.74 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CTI BioPharma Corp. (CTIC) measures how much investors pay for each dollar of the company's trailing earnings. CTIC's current PE ratio of N/A is calculated by dividing its stock price of $9.10 by its TTM earnings per share of -$0.79.
Frequently asked questions
CTIC pe ratio · 6 questionsCTIC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $9.10 and TTM EPS of -$0.79. Data sourced from Financial Modeling Prep via CTIC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CTI BioPharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09